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Abstract. Epidermal growth factor receptor (EGFR) muta-
tion is a favorable prognostic factor of non-small cell lung 
cancer (NSCLC). In the majority of patients with EGFR 
mutations, clinical benefits of EGFR-tyrosine kinase inhibi-
tors (TKIs) have been reported. One of the TKIs, gefitinib, 
appears to be less toxic to the skin than other TKIs. The 
present study reports a case of NSCLC with EGFR muta-
tion (exon 19 deletion) in which dose‑reduced gefitinib was 
effective against recurrence. Due to development of a grade 3 
skin adverse event (AE) after 2 months of daily administration 
of gefitinib, the frequency of administration of gefitinib was 
reduced to every other day for 2 weeks. As the AE continued, 
the frequency of administration was reduced to once every 
3 days. The patient has been in remission for 27 months since 
treatment with 250 mg gefitinib once every 3 days was initi-
ated, which is the lowest dose to be reported in a successfully 
treated case of NSCLC with EGFR mutation. Dose reduction 
of gefitinib might be appropriate for patients with severe AEs 
and should be considered as a treatment option after 1 or 
2 months of regular daily dosing of gefitinib if there is no other 
satisfactory treatment option.
Introduction
Non-small cell lung cancer (NSCLC) remains a refractory 
disease, even in the era of development of molecular-targeting 
agents. Mutated epidermal growth factor receptor (EGFR) 
is a favorable prognostic factor; it is observed in 20-30% of 
cases, and the incidence is high in the Asian population (1). 
EGFR-tyrosine kinase inhibitors (TKIs) have been recog-
nized as key drugs for NSCLC; the majority of studies have 
reported their effectiveness in the treatment of EGFR-mutated 
NSCLC (2). The present study reports a case of NSCLC with 
EFGR mutation in which the administration of gefitinib was 
reduced to once every 3 days.
Case report
A 65-year-old woman with no medical history presented with 
the incidental detection of a nodule 34 mm in diameter on 
chest radiography at the Mito Medical Center of the University 
of Tsukuba (Mito, Japan). The patient was asymptomatic 
and had been in good health. The physical examination was 
unremarkable. The chest computed tomography (CT) scan 
revealed a well-circumscribed mass in the middle lobe of 
the lung that measured 34x30x24 mm with specular appear-
ance (Fig 1). The routine laboratory tests were normal, as 
were tumor markers including carcinoembryonic antigen. The 
patient was diagnosed with adenocarcinoma on the basis of 
cytological examination of transbrochial biopsy specimens. 
Distant metastasis was not detected. The patient underwent 
lobectomy of the middle of the lung and mediastinal lymph 
node dissection. The patient's pleural fluid was malignant and 
the final pathological diagnosis was lung adenocarcinoma 
staged as pT4bN2M1a, stage IV. An EGFR exon 19 deletion 
was identified. Soon after the surgical resection, the patient 
received five courses of chemotherapy with carboplatin and 
paclitaxel. In addition, the patient was treated with uracil 
and tegafur (UFT; Taiho Pharmaceutical Co., Ltd., Tokyo, 
Japan) for 6 months. However, 24 months after the surgery, 
four metastatic lesions ≤15 mm in diameter were identified in 
the right lung (Fig 2). A cerebellar metastasis with a diameter 
of 16 mm was also observed in brain magnetic resonance 
imaging (MRI) (Fig 3), which was treated with gamma knife 
radiotherapy. Thereafter, treatment with 250 mg gefitinib once 
daily was initiated. A chest CT scan after 1 month of gefitinib 
administration revealed that the pulmonary metastatic tumors 
in the right lower lobe of the lung had disappeared. A grade 3 
skin adverse effect (AE) according to the National Cancer 
Institute Common Toxicity Criteria (version 4.0) was present. 
Due to the AE, the administration of gefitinib was changed to 
every other day following daily administration for 2 months. 
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However, the skin AE continued and the patient requested 
further dose reduction. After discontinuation of gefitinib for 
1 week, treatment was restored at a frequency of once every 
3 days. Treatment with gefitinib was continued in the outpa-
tient clinic without tumor recurrence, including in the lung 
as well as in the brain, for 27 months from the initiation of 
the reduction in frequency of gefitinib treatment to once every 
3 days. Informed consent was obtained from the patient prior 
to treatment.
Discussion
Gefitinib has been reported to be the preferred choice of treat-
ment for NSCLC with EGFR mutation (2). Three previous case 
reports of successful treatment with a low dose of gefitinib 
exist, and they are restricted to elderly patients and patients 
with severe AEs (3-5). Hanaoka et al reported a case of post-
operative recurrent lung cancer in an octogenarian patient 
that responded to treatment with radiation and gefitinib. The 
authors considered that a useful treatment option for octoge-
narians with postoperative recurrent lung cancer could be the 
administration of gefitinib every other day following daily 
administration for two weeks (3). Tomisaki et al reported the 
successful treatment of a patient with advanced lung cancer 
and brain metastasis after gamma knife radiotherapy and 
chemotherapy, when gefitinib was administered every other 
day. The frequency of administration of gefitinib was reduced 
Figure 1. Chest computed tomography scan at the time of first presentation revealed a mass in the middle lobe of the lung.
Figure 2. Follow‑up chest computed tomography scan, performed 24 months after the surgery, detected pulmonary metastatic tumors ≤15 mm in the right 
lung (arrows).
Figure 3. Follow-up brain magnetic resonance imaging, performed 24 months 
after the surgery, detected a cerebellar metastasis (arrow).
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to every other day because of grade 3 skin reaction and rash (4). 
The reduction was initiated following the discontinuation of 
treatment after 1 month of daily administration of gefitinib (4). 
Kitamura et al reported a case who remained in good condi-
tion over 5 years with the administration of gefitinib every 
other day (5). Very recently, we also evaluated the dose reduc-
tion of TKIs in the treatment of NSCLC (6). In the patients 
tested, not only patients with AEs but also elderly patients and 
patients with low body surface area underwent dose reduction 
of TKIs (6). Notably, the progression-free survival of patients 
who underwent dose reduction was not shorter than that of the 
patients who did not undergo dose reduction (6).
Currently, the present case has been in remission from lung 
adenocarcinoma for 27 months with once every 3 day adminis-
tration of 250 mg gefitinib, which, to the best of our knowledge, 
is the lowest dose to be reported in a successfully treated case 
of EGFR-mutated NSCLC. In this case, dose reduction was 
performed due to skin AE. The patient was treated with gefi-
tinib daily for 2 months, every other day for 1 month and then 
once every 3 days. From the results of previous studies (3-6) 
and the present one, it is speculated that dose reduction would 
be indicated in patients who respond well to the daily adminis-
tration of gefitinib for >1 month, if required.
In the present case, measurements of serum gefitinib 
levels were not taken. There have been certain reports 
showing that the serum levels of gefitinib have an association 
with the effect of the drug (7,8). By contrast, other studies 
did not confirm the association (9-11). At present, therefore, 
it remains beyond our knowledge to whom exactly the reduc-
tion of gefitinib dosage should be permitted without any loss 
of clinical efficacy.
In summary, the present study describes a case in which 
dose‑reduced gefitinib was effective and a 27-month disease 
control was achieved. However, such an irregular administra-
tion of gefitinib is not recommended. Dose reduction may be 
an alternative treatment option to be considered for patients 
who respond well to gefitinib, in cases where there is no other 
satisfactory choice of treatment.
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